MDxHealth Future Growth

Future criteria checks 1/6

MDxHealth is forecast to grow earnings and revenue by 59.8% and 15.5% per annum respectively while EPS is expected to grow by 66.7% per annum.

Key information

59.8%

Earnings growth rate

66.7%

EPS growth rate

Biotechs earnings growth42.3%
Revenue growth rate15.5%
Future return on equityn/a
Analyst coverage

Low

Last updated18 Dec 2023

Recent future growth updates

Recent updates

Why Investors Shouldn't Be Surprised By MDxHealth SA's (EBR:MDXH) 29% Share Price Plunge

Oct 05
Why Investors Shouldn't Be Surprised By MDxHealth SA's (EBR:MDXH) 29% Share Price Plunge

MDxHealth (EBR:MDXH) Has Debt But No Earnings; Should You Worry?

Aug 29
MDxHealth (EBR:MDXH) Has Debt But No Earnings; Should You Worry?

MDxHealth (EBR:MDXH) Is Carrying A Fair Bit Of Debt

Apr 21
MDxHealth (EBR:MDXH) Is Carrying A Fair Bit Of Debt

Is MDxHealth (EBR:MDXH) Using Debt In A Risky Way?

May 05
Is MDxHealth (EBR:MDXH) Using Debt In A Risky Way?

Here's Why MDxHealth (EBR:MDXH) Can Manage Its Debt Despite Losing Money

Nov 08
Here's Why MDxHealth (EBR:MDXH) Can Manage Its Debt Despite Losing Money

MDxHealth (EBR:MDXH) Has Debt But No Earnings; Should You Worry?

Mar 23
MDxHealth (EBR:MDXH) Has Debt But No Earnings; Should You Worry?

MDxHealth's (EBR:MDXH) Stock Price Has Reduced 75% In The Past Five Years

Jan 29
MDxHealth's (EBR:MDXH) Stock Price Has Reduced 75% In The Past Five Years

Is MDxHealth (EBR:MDXH) Weighed On By Its Debt Load?

Nov 27
Is MDxHealth (EBR:MDXH) Weighed On By Its Debt Load?

Earnings and Revenue Growth Forecasts

ENXTBR:MDXH - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202596-13-314
12/31/202482-26-20-155
12/31/202370-43-26-205
9/30/202364-45-30-24N/A
6/30/202355-48-35-29N/A
3/31/202346-47-34-30N/A
12/31/202237-44-38-34N/A
9/30/202230-40-32-30N/A
6/30/202225-34-28-26N/A
3/31/202223-31N/AN/AN/A
12/31/202122-29-23-23N/A
9/30/202121-28-22-21N/A
6/30/202119-28-21-21N/A
3/31/202119-28N/AN/AN/A
12/31/202018-29-21-20N/A
9/30/202015-36-20-20N/A
6/30/202011-43-20-20N/A
3/31/202011-43-21-21N/A
12/31/201912-43-22-22N/A
9/30/201917-37-25-25N/A
6/30/201922-31-28-27N/A
3/31/201925-32-29-28N/A
12/31/201828-32-30-29N/A
9/30/201831-30-30-28N/A
6/30/201833-28-31-27N/A
3/31/201837-20-23-19N/A
12/31/201741-12-15-10N/A
9/30/201741-9-13-8N/A
6/30/201741-5N/A-5N/A
3/31/201736-9N/A-11N/A
12/31/201630-13N/A-17N/A
9/30/201626-15N/A-17N/A
6/30/201623-17N/A-16N/A
3/31/201620-16N/A-15N/A
12/31/201518-14N/A-14N/A
9/30/201516-14N/A-15N/A
6/30/201515-13N/A-15N/A
3/31/201513-14N/A-17N/A
12/31/201412-15N/A-19N/A
9/30/201410-16N/A-19N/A
6/30/20148-16N/A-19N/A
3/31/20148-16N/A-17N/A
12/31/20138-16N/A-14N/A
9/30/20137-15N/A-13N/A
6/30/20137-14N/A-12N/A
3/31/20137-13N/A-11N/A
12/31/20126-12N/A-11N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MDXH is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MDXH is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MDXH is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MDXH's revenue (15.5% per year) is forecast to grow faster than the Belgian market (5.6% per year).

High Growth Revenue: MDXH's revenue (15.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MDXH's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/12/18 19:21
End of Day Share Price 2023/12/18 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MDxHealth SA is covered by 13 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael Ruzic-GauthierBerenberg
Mark MassaroBTIG
Roderick VerhelstDegroof Petercam